NephRx Corporation, founded in 1995 and based in Kalamazoo, Michigan, is a biotechnology company dedicated to discovering and developing therapeutic products for the treatment of acute kidney failure, renal disorders, and gastrointestinal diseases. The company's core mission is to improve patient outcomes through innovative treatments. NephRx's product portfolio includes NX001, aimed at treating delayed graft function in kidney transplant patients, and NX002, a peptide derived from the naturally occurring growth factor AMP-18.
NephRx has been supported by notable investors in the biotechnology sector. The company has achieved significant milestones in its research and development efforts, particularly in advancing its lead compounds towards clinical trials. By focusing on unmet medical needs in renal and gastrointestinal health, NephRx has made a meaningful impact in the biotech industry, contributing to the advancement of therapeutic options for patients with severe health conditions.
